OR WAIT null SECS
The HCPLive ADHD condition center page is a comprehensive resource for clinical news and insights on ADHD. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for ADHD.
October 18, 2023
Article
Solriamfetol could potentially serve as a new ADHD treatment if future research goes positively.
October 17, 2023
Solriamfetol, typically used to treat narcolepsy and sleep apnea, has demonstrated it can reduce ADHD symptoms with no adverse cardiovascular effects.
August 28, 2023
These approvals of generics by the FDA can help to provide for patients with ADHD or BED the same clinical benefits as well as risks as the drugs’ brand-name counterparts.
July 12, 2023
The analysis of 500+ patients with ADHD shows no statistically significant evidence linking stimulant treatment to later substance use, indicating that stimulant medication did not increase or decrease the risk of substance use in adolescence or adulthood.
June 27, 2023
Video
Telehealth likely will have a major place in psychiatric care in the future.
June 01, 2023
Participants who only initiated non-stimulant therapy for ADHD had significantly greater odds of past-year prescription stimulant misuse than the population controls.
May 30, 2023
The rate of sleep apnea is greater in patients with bipolar disorder and depression.
May 19, 2023
Dr. Levine talks with Marketa Wills, MD, about the role of the payer in medicine.
April 28, 2023
April 26, 2023
Treatment with benzodiazepines, antipsychotics, and antidepressants was associated with an increased risk of all-cause hospitalization or mortality, while mood stabilizer treatment did not have a statistically significant association with any of the predetermined outcomes and ADHD medications were linked to a lower risk of psychiatric hospitalization.